Target intelligence / Profile preview

Shigella flexneri serotype 1b lipopolysaccharide O-antigen (S. flexneri 1b O-antigen) (S. flexneri 1b O-antigen)

Target
S. flexneri 1b O-antigen
Molecular classification
Polysaccharide, Bacterial surface antigen, Lipopolysaccharide component
01

Overview

Shigella flexneri serotype 1b lipopolysaccharide O-antigen is a surface-exposed polysaccharide that constitutes the outermost part of the lipopolysaccharide (LPS) layer in the Gram-negative bacterium Shigella flexneri [4, 10]. It is composed of a repeating tetrasaccharide unit consisting of three L-rhamnose residues and one N-acetylglucosamine, with specific O-acetylation at the RhaI residue and glucosylation at the RhaII residue defining the 1b serotype [7, 12]. This molecule plays a vital role in bacterial pathogenesis by facilitating cell-to-cell spread, providing resistance to environmental stresses like stomach acid, and aiding in immune evasion [4, 11]. As the primary target for protective humoral immunity, the 1b O-antigen is a central component in multivalent vaccine candidates, including glycoconjugates and Generalized Modules for Membrane Antigens (GMMA) [1, 12, 14]. These vaccines aim to elicit serotype-specific bactericidal antibodies to prevent shigellosis, a major cause of bacillary dysentery and childhood mortality in low-resource settings [8, 14]. Therapeutic challenges include the high diversity of Shigella serotypes and the need for broad-spectrum coverage to prevent serotype replacement [1, 12].

Other names
Shigella flexneri 1b O-polysaccharideS. flexneri 1b O-AgShigella flexneri serotype 1b LPS O-antigenSomatic antigen 1b
02

Mechanism of action

Induction of protective humoral immunity, specifically anti-O-antigen IgG, which provides serotype-specific protection through serum bactericidal activity and the blocking of bacterial invasion into the colonic epithelium [8, 12, 14].

03

Biological functions

Bacterial cell wall integrityImmune evasionPathogenesisSerotype specificityAcid resistance
04

Disease associations

InfectionShigellosisBacillary dysentery
05

Safety considerations

Serotype-specific protection [12]Serotype replacement [1, 12]Endotoxicity [12]Lack of cross-reactivity [12, 13]
06

Interacting drugs

altSonflex1-2-3 (GMMA vaccine candidate) [1, 14]

3 more in the full profile.

07

Biomarkers

Anti-O-antigen IgG titers [8]Serum bactericidal activity (SBA) [1, 8]Fecal IgA [9]

Beyond the preview

Go deeper on Shigella flexneri serotype 1b lipopolysaccharide O-antigen (S. flexneri 1b O-antigen) (S. flexneri 1b O-antigen).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shigella flexneri serotype 1b lipopolysaccharide O-antigen (S. flexneri 1b O-antigen) (S. flexneri 1b O-antigen).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call